Fluoxetine-induced perinatal morbidity in a sheep model

Selective serotonin reuptake inhibitors (SSRI) are the most common antidepressants used by pregnant women. However, adverse pregnancy outcomes have been described in women taking SSRI during pregnancy—placental lesions, premature birth, poor neonatal adaptation. We aimed to investigate the effects of fluoxetine (Prozac® most commonly used SSRI) treatment during the last month of gestation on pregnancy complications, placental and neonatal health in a non-depressed sheep model. On day 119 ± 1 postbreeding (experimental day 0; E0) of a 151-day expected gestation, Hampshire ewes were randomly assigned to receive fluoxetine (n = 9 ewes, 15 lambs; daily intravenously treatment with 10 mg/kg on E0 and E1 and 5 mg/kg daily thereafter until parturition) or to a control group (n = 10; 14 lambs; vehicle only). Blood samples from ewes were collected throughout the experimental period and postpartum; blood from lambs were collected postpartum. Analysis of variance was used for statistical analysis. Fluoxetine treatment reduced placentome growth during the last month of pregnancy. Gestation length was decreased by 4.5 days in fluoxetine-treated ewes. Birthweight was reduced in lambs exposed to fluoxetine in utero; weights remained decreased until postnatal day 3. Placentome diameter by birthweight ratio was not different between groups suggesting that the decreased placentome diameter was accompanied by decreased lamb birthweight. During the first week postnatal, lambs exposed to fluoxetine in utero had decreased blood pH and decreased total carbon dioxide, bicarbonate, and base excess and increased lactate (days 3–6), collectively indicative of metabolic acidemia. Additionally, ionized calcium was decreased between postnatal days 0 to 4 in lambs exposed to fluoxetine in utero. Using a non-depressed animal model clearly defines a role for SSRI on the occurrence of perinatal complications and neonatal morbidity. The decreased placentome diameter, shortened gestation, decreased birthweight, decreased calcium levels, and neonatal acidemia suggest the occurrence of intrauterine growth restriction. The persistence of neonatal acidemia for several days postpartum suggests poor neonatal adaptation to extrauterine environment.

[1]  L. Hernandez,et al.  Pregnancy Complications and Neonatal Mortality in a Serotonin Transporter Null Mouse Model: Insight Into the Use of Selective Serotonin Reuptake Inhibitor During Pregnancy , 2022, Frontiers in Medicine.

[2]  L. Hernandez,et al.  Effect of Low and High Doses of Two Selective Serotonin Reuptake Inhibitors on Pregnancy Outcomes and Neonatal Mortality , 2022 .

[3]  Meng Wang,et al.  Female fertility under the impact of COVID-19 pandemic: a narrative review , 2021, Expert Reviews in Molecular Medicine.

[4]  G. Piccione,et al.  Daily dynamic changes of blood acid-base status and vital parameters in lambs and goat kids over the first seven days after birth , 2021 .

[5]  S. Weaver,et al.  Elevated serotonin coordinates mammary metabolism in dairy cows , 2021, Physiological reports.

[6]  Shiliang Liu,et al.  The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis , 2021, Canadian Medical Association Journal.

[7]  Ricka Messer,et al.  Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures , 2021, Pediatrics.

[8]  Roopa R. Shinde,et al.  Placental pathology in intrauterine growth retardation , 2020 .

[9]  C. Chambers,et al.  Prenatal Antidepressant Use and Risk of Adverse Neonatal Outcomes , 2020, Pediatrics.

[10]  B. Błaszczyk,et al.  Morphometric measurements of the umbilical cord and placentomes and Doppler parameters of the umbilical artery through ultrasonographic analysis in pregnant sheep , 2020 .

[11]  J. Bar,et al.  Maternal use of selective serotonin reuptake inhibitors (SSRI) during pregnancy—neonatal outcomes in correlation with placental histopathology , 2020, Journal of Perinatology.

[12]  C. Rosenfeld Placental serotonin signaling, pregnancy outcomes, and regulation of fetal brain development† , 2019, Biology of Reproduction.

[13]  W. Dean,et al.  Mechanisms of early placental development in mouse and humans , 2019, Nature Reviews Genetics.

[14]  D. Walker,et al.  Disrupted placental serotonin synthetic pathway and increased placental serotonin: Potential implications in the pathogenesis of human fetal growth restriction. , 2019, Placenta.

[15]  J. Petersen,et al.  Real supermodels wear wool: summarizing the impact of the pregnant sheep as an animal model for adaptive fetal programming , 2019, Animal frontiers.

[16]  P. Ebeling,et al.  The relationship between the placental serotonin pathway and fetal growth restriction. , 2019, Biochimie.

[17]  A. Charles,et al.  The Possible Role of Placental Morphometry in the Detection of Fetal Growth Restriction , 2019, Front. Physiol..

[18]  Su-xia Cao,et al.  A meta-analysis of selective serotonin reuptake inhibitors (SSRIs) use during prenatal depression and risk of low birth weight and small for gestational age. , 2018, Journal of affective disorders.

[19]  C. Qiao,et al.  Prenatal Selective Serotonin Reuptake Inhibitor Use and Associated Risk for Gestational Hypertension and Preeclampsia: A Meta-Analysis of Cohort Studies. , 2018, Journal of women's health.

[20]  M. Khademi,et al.  Effect of maternal fluoxetine exposure on lung, heart, and kidney development in rat neonates , 2018, Iranian journal of basic medical sciences.

[21]  D. Roberts,et al.  Serotonin transporter protects the placental cells against apoptosis in caspase 3‐independent pathway , 2017, Journal of cellular physiology.

[22]  L. Hui,et al.  Reduced growth velocity across the third trimester is associated with placental insufficiency in fetuses born at a normal birthweight: a prospective cohort study , 2017, BMC Medicine.

[23]  L. Forsberg,et al.  Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy , 2016, Pediatrics.

[24]  C. Chambers,et al.  Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence , 2016, CNS Drugs.

[25]  S. Lehto,et al.  Maternal Use of Selective Serotonin Reuptake Inhibitors and Lengthening of the Umbilical Cord: Indirect Evidence of Increased Foetal Activity—A Retrospective Cohort Study , 2016, PloS one.

[26]  S. Morgan,et al.  Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy , 2016, Obstetrics and gynecology.

[27]  T. Morgan,et al.  Role of the Placenta in Preterm Birth: A Review , 2016, American Journal of Perinatology.

[28]  A. Robb,et al.  SSRI use during pregnancy. , 2015, Seminars in perinatology.

[29]  A. David,et al.  Animal models of fetal growth restriction: Considerations for translational medicine. , 2015, Placenta.

[30]  R. Morris,et al.  Serotonin syndrome in a breast-fed neonate , 2015, BMJ Case Reports.

[31]  M. Bonati,et al.  Neonatal Toxicity Following Maternal Citalopram Treatment , 2013, Fetal and pediatric pathology.

[32]  N. Goeden,et al.  Placental serotonin: implications for the developmental effects of SSRIs and maternal depression , 2013, Front. Cell. Neurosci..

[33]  P. Marcorelles [Placental features in intrauterine growth retardation]. , 2013, Journal de gynecologie, obstetrique et biologie de la reproduction.

[34]  C. Vannucchi,et al.  A clinical and hemogasometric survey of neonatal lambs , 2012 .

[35]  S. Morrison,et al.  Serotonin and Blood Pressure Regulation , 2012, Pharmacological Reviews.

[36]  A. Ornoy,et al.  Selective Serotonin Reuptake Inhibitors in Human Pregnancy: To Treat or Not to Treat? , 2011, Obstetrics and gynecology international.

[37]  E. Deneris,et al.  A transient placental source of serotonin for the fetal forebrain , 2011, Nature.

[38]  M. Ansorge,et al.  Impact of antenatal selective serotonin reuptake inhibitor exposure on pregnancy outcomes in mice. , 2010, American journal of obstetrics and gynecology.

[39]  J. Hernández-Rodríguez,et al.  Another Abnormal Trait in the Serotonin Metabolism Path in Intrauterine Growth-Restricted Infants , 2008, Neonatology.

[40]  J. Morrison SHEEP MODELS OF INTRAUTERINE GROWTH RESTRICTION: FETAL ADAPTATIONS AND CONSEQUENCES , 2008, Clinical and experimental pharmacology & physiology.

[41]  S. Gwaltney-Brant,et al.  Serotonin: a review. , 2008, Journal of veterinary pharmacology and therapeutics.

[42]  C. Vio,et al.  Pregnant Rats Treated With a Serotonin Precursor Have Reduced Fetal Weight and Lower Plasma Volume and Kallikrein Levels , 2007, Hypertension.

[43]  C. Hertzman,et al.  Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. , 2006, Archives of general psychiatry.

[44]  A. Wieck,et al.  Neonatal symptoms following maternal paroxetine treatment: Serotonin toxicity or paroxetine discontinuation syndrome? , 2005, Journal of psychopharmacology.

[45]  A. Egberts,et al.  Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. , 2004, Archives of internal medicine.

[46]  Pal Pacher,et al.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? , 2004, Current pharmaceutical design.

[47]  C. DeVane Metabolism and Pharmacokinetics of Selective Serotonin Reuptake Inhibitors , 1999, Cellular and Molecular Neurobiology.

[48]  U. Ekblad,et al.  Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. , 2003, Archives of general psychiatry.

[49]  W. Reik,et al.  Placental-specific IGF-II is a major modulator of placental and fetal growth , 2002, Nature.

[50]  P. Castrogiovanni,et al.  Serotonin and Fluoxetine Levels in Plasma and Platelets After Fluoxetine Treatment in Depressive Patients , 2002, Journal of clinical psychopharmacology.

[51]  J. Morrison,et al.  Effect of Maternal Fluoxetine Administration on Uterine Blood Flow, Fetal Blood Gas Status, and Growth , 2002, Pediatric Research.

[52]  S. Bakry,et al.  Fluoxetine Hcl Induced Intrauterine Foetal Growth Retardation And Skeletal Malformation In Pregnant Mice , 2002 .

[53]  I. Whyte,et al.  Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? , 2001, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[54]  U. Lang,et al.  Systemic and uterine vascular response to serotonin in third trimester pregnant ewes. , 1993, European journal of obstetrics, gynecology, and reproductive biology.

[55]  G. Manjarrez,et al.  Newborn humans and rats malnourished in utero: free plasmal-tryptophan, neutral amino acids and brain serotonin synthesis , 1989, Brain Research.

[56]  R. Marsboom,et al.  Protective activity of ketanserin against serotonin‐induced embryotoxicity and teratogenicity in rats , 1986 .

[57]  J. Robson,et al.  Mechanism of inhibitory action of 5-hydroxytryptamine on placental function. , 1967, American journal of obstetrics and gynecology.

[58]  J. Robson,et al.  Mechanism of lethal action of 5-hydroxytryptamine on the foetus. , 1963, The Journal of endocrinology.